Clinical Trial Detail

NCT ID NCT02689336
Title Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Recruitment Recruiting
Gender
Phase Phase II
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

Advanced Solid Tumor

Therapies

Erlotinib + Temozolomide

Age Groups: adult child

Additional content available in CKB BOOST